Navigation Links
Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
Date:2/17/2013

ZURICH, February 18, 2013 /PRNewswire/ --

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia. The new results are from a  recent double-blind, randomized, placebo controlled, parallel group, non-confirmatory, sleep-laboratory study. The study evaluated piromelatine compared to placebo in 120 adult primary insomnia patients ages 18 years and older.

Piromelatine 20/50mg treatment for 4 weeks resulted in statistically significant and clinically meaningful improvements relative to placebo in key  polysomnographic (PSG) parameters including Wake After Sleep Onset (WASO) (p=0.02 for both doses) and in particular WASO for the first 6 hours of sleep (WASO-6h) (p=0.0008 and p=0.04 for the 50 mg and 20 mg groups, respectively). Piromelatine 50 mg also improved Sleep Efficiency (SEF) (p=0.02), Total Sleep Time (TST) (p=0.02), Total Time Awake (TTA) (p=0.01) and time in NREM sleep (p=0.028) indicating beneficial effects on sleep maintenance. Subjective improvements relative to placebo in quality of sleep and total sleep time measured by the Pittsburg Sleep Quality Questionnaire (PSQI) were also observed, confirming the PSG findings. Piromelatine enhanced NREM sleep EEG delta power and significantly reduced beta power (p<0.05). The decrease in EEG beta activity, a marker of cortical arousal, is a physiological surrogate marker of the efficacy of Piromelatine in sleep maintenance. Piromelatine was generally safe and well tolerated, had no detrimental effects on next-day psychomotor performance (as assessed by the Digit Symbol Substitution Test (DSST)) for any dose group and no deleterious effects on sleep structure and architecture.

"Piromelatine demonstrates a good potential for the treatm
'/>"/>

SOURCE Neurim Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Pulse Light Clinic in London,s ... as part of their ongoing research into the condition. They ... their Rosacea. The survey participants were aged between 20 and ... women. The results revealed some rather surprising statistics: ... attempt to visit their GP for Rosacea treatment. ...
(Date:6/30/2015)... , June 30, 2015 First Choice ... to the Astanza Duality and is the only clinic ... offering professional tattoo removal treatments. The practice has recently ... Removal brand to showcase their focus in the ... residents better results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... 2015  Avanir Pharmaceuticals, Inc. today announced top-line ... treatment with NUEDEXTA ® was associated with ... affect (PBA) in patients with traumatic brain injury ... characterized by sudden and uncontrollable outbursts of laughing ... brain injury. PRISM II is a phase IV ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... Calif., Jan. 26, 2012  Cardica, Inc. (Nasdaq: CRDC ... its fiscal second quarter ended December 31, 2011, on Monday, ... host a conference call at 4:30 p.m. Eastern Time to ... company,s business. Conference Call Details ...
... LONDON, Jan. 26, 2012  The IP & Science ... with Brazil,s Institute for Applied Economic Research (IPEA). ... and Policies for Innovation, Regulation and Infrastructure (DISET) ... suite of products, supplying them with generic pharmaceutical ...
Cached Medicine Technology:Cardica to Announce Fiscal 2012 Second Quarter Financial Results on Monday, February 6, 2012 2Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Opportunities in the Generic Drug Landscape 2
(Date:6/30/2015)... Minn. (PRWEB) , ... June 30, 2015 , ... The ... million in funding for 24 projects across the state. The projects improve community health ... range from $25,000 to $100,000 and many are renewable for a second year in ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier provider of ... Mann, CPC, RCC, ROCC, Coding Documentation and Education Manager, was honored at the ... for her contribution to the RBMA Coding Subcommittee. , Ms. Mann served ...
(Date:6/30/2015)... Chicago, IL (PRWEB) , ... June 30, 2015 , ... ... to educate women on fertility preservation and deciding the right age to pursue egg ... child until after the age of 35 — a 150 percent increase since the ...
(Date:6/30/2015)... San Diego, California (PRWEB) , ... June 30, 2015 , ... ... Sullivan Solar Power today at a media event in San Diego. Speakers and clean ... San Diego School of medicine, Natalie Germuska of Kindred Hospital, and Daniel Sullivan, founder ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... today that they have been awarded the exclusive billing agreements with Jackson Radiology ... of billing services encompassing their proprietary suite of billing process software functionality called ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota Foundation Awards $1.5 Million 2Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2
... has roped in Bayer HealthCare to market its recombinant ... //said in a statement Wednesday. ,The Bangalore-based ... 2007-08 after completing the registration trials and seeking the ... will be extended to other countries in the Asia-Pacific ...
... of the Center for Organic and Medicinal Chemistry F. ... Problems of Drug Dependence's 2006 Nathan B. Eddy Memorial ... addiction. ,Carroll has led RTI research focusing ... Among his many achievements, Carroll developed RTI-336 and JDTic, ...
... University researchers it was found that by appreciating how ... options can be developed to help patients suffering from ... causes of heart attack and stroke. The study, released ... a gene called heme oxygenase-1 (HO-1) markedly protects the ...
... study conducted by the researchers at the Mayo clinic it is ... particular type of heart failure.// ,The data was collected ... that there is a rise in the number of diastolic heart ... half of heart failure cases. The results of the study were ...
... particularly in terms of economic growth, could take a severe ... a UN report said here today. // ,The ... the likely impact of the epidemic over a 14-year period ... of HIV/AIDS, the country's economic growth over the next 10-15 ...
... has been highlighted again by the preliminary judgement yesterday ... ,Eight years ago Senator Henry, a medical ... regulate such clinics. Recently, Health Minister Mary Harney asked ... assisted human reproduction in Ireland. ,According to ...
Cached Medicine News:Health News:Bayer to Market Biocon Insulin in China 2Health News:Scientist Recognized for Drug Addiction Research 2Health News:Genes Identified To Protect Heart Muscles 2Health News:Diastolic Heart Failure on the Rise 2Health News:Regulation of Infertility Clinics Needed 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: